US20170312260A1 - New indication of azelnidipine pharmaceutical composition for treating cancer - Google Patents

New indication of azelnidipine pharmaceutical composition for treating cancer Download PDF

Info

Publication number
US20170312260A1
US20170312260A1 US15/521,500 US201515521500A US2017312260A1 US 20170312260 A1 US20170312260 A1 US 20170312260A1 US 201515521500 A US201515521500 A US 201515521500A US 2017312260 A1 US2017312260 A1 US 2017312260A1
Authority
US
United States
Prior art keywords
cancer
azelnidipine
min min
cell lines
average
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/521,500
Inventor
Chiu-Hung Chen
Show-Mei CHUANG
Tzong-Der Way
Nai-Wan HSIAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Launx Biomedical Co Ltd
Original Assignee
Launx Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Launx Biomedical Co Ltd filed Critical Launx Biomedical Co Ltd
Priority to US15/521,500 priority Critical patent/US20170312260A1/en
Publication of US20170312260A1 publication Critical patent/US20170312260A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention related to a new indication of Azelnidipine pharmaceutical composition, especially related to inhibition effect of Azelnidipine pharmaceutical composition on a variety of cancer cells.
  • Azelnidipine is a drug for treating hypertension and can be used alone or in combination with other antihypertensive drugs. Azelnidipine is approved by FDA and accumulated a huge data of drug use and drug mechanism research.
  • cancer is the most popular disease cause of death in the world.
  • the cancer patients are gradually increase yearly, therefore the treatment method of the cancer has become an important issue.
  • the medical treatments of cancer can be classified as surgical treatment, radiation therapy, chemotherapy and target therapy.
  • the cancer drug whether chemotherapy drug or target therapy drug, is to inhibit cancer cells duplication and split to prevent the tumor growth and metastasis. Averagely, only about five of 10,000 new drugs can successfully enter the phase I of clinical trials. Furthermore, if the cancer patients happen the drug resistance, that would reduce the effectiveness of the drugs and result in the medical treatment failure. Therefore, the new drug development is very difficult.
  • the present invention provide the development of new cancer clinical indications of Azelnidipine.
  • the present invention provides a new indication of Azelnidipine.
  • the experimental results showed that the Azelnidipine had no toxicity or had little toxicity to normal cells in the present invention. However, the selective effect of Azelnidipine between normal cells and cancer cells need to be identified.
  • the present invention provides a pharmaceutical composition of Azelnidipine for treating cancer.
  • the pharmaceutical composition is composed of effective dose of Azelnidipine and a pharmaceutical acceptable salt.
  • the cancer is selected from pleural-related cancer, abdominal-related cancer, endocrine-related cancer, gastrointestinal tract-related cancer.
  • the cancer is selected from osteosarcoma, skin cancer and blood cancer.
  • the pleural-related cancer is lung cancer.
  • the abdominal-related cancer is selected from bladder cancer, cervical cancer, and kidney cancer.
  • the endocrine-related cancer is selected from prostate cancer, breast cancer, and ovarian cancer.
  • the gastrointestinal tract-related cancer is selected from gastric cancer, hepatic cancer, colorectal cancer, pancreatic cancer, and tongue cancer.
  • the effective dose of Azelnidipine is from 2.0 mg/kg/day to 500 mg/kg/day.
  • FIG. 1 shows the results of the inhibitory effect of the different cancer cells by Azelnidipine.
  • FIG. 2 shows the results of the inhibitory effect of tumor volume by Azelnidipine.
  • FIG. 3 shows the inhibitory effect of tumor growth via administered high-dose and low-dose of Azelnidipine.
  • the cancer cells includes lung cancer, gastric cancer, hepatic cancer, colon cancer, skin cancer, cervical cancer, prostate cancer, bladder cancer, breast cancer, leukemia, pancreatic cancer, ovarian cancer, tongue cancer, osteosarcoma, and renal cancer.
  • the normal cells used in the control group included kidney cell (HEK293) and human bronchial epithelial cell line BEAS-2B (as shown in Table 1).
  • Cancer cell lines were cultured in different culture medium according to different characteristics (as shown in Table 1). The cell numbers were counted and reseed as 2 ⁇ 10 6 in cell culture plate/flask. Then, the culture medium were added to a volume of 10 ml, and the cells were cultured for 2-3 days. Then, the cells were suspended for loading into 96-well plates. The number of cells was 3000 and the volume of the culture medium was 100 ⁇ l each well.
  • This inhibition test of Azelnidipine on pleural-related cancer cells were using two lung cancer cell lines A549 and H1650.
  • the inhibitory tests of Azelnidipine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 2.
  • This inhibition test of Azelnidipine on endocrine-related cancer cells were using prostate cancer cell line PC-3 (Table 6), breast cancer cell lines MCF7 and MDA-MB-231 (Table 7), and ovarian cancer cell lines NIH-OVCAR-3 and TOV-21G (Table 8).
  • the inhibitory tests of Azelnidipine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 6, Table 7, and Table 8.
  • This inhibition test of Azelnidipine on gastrointestinal tract-related cancer cells were using gastric cancer cell lines AGS and MKN-45 (Table 9), hepatic cancer cell lines HepG2 and Hep3B (Table 10), colorectal cancer cell lines HCT116-wt and LoVo (Table 11), pancreatic cancer cell lines AsPC-1 and BxPC-3 (Table 12), tongue cancer cell line SAS (Table 13).
  • the inhibitory tests of Azelnidipine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 9, Table 10, Table 11, Table 12 and Table 13.
  • This inhibition test of Azelnidipine on other cancer cells were using osteosarcoma cell line U2OS (Table 14), skin cancer cell lines A375 and BCC (Table 15). The inhibitory tests of Azelnidipine were performed 3 to 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 14 and Table 15.
  • mice were (BALB/cAnN.Cg-Foxn1 nu /CrlNarl) purchased from National Laboratory Animal Center (Taiwan)). The weight of the mice were 21 ⁇ 1 g. These mice were subcutaneously injected with gastric cancer cells (AGS) and then put these mice into different cages at random. The drug test experiment was divided into three groups, include “normal control group”, “low dose group (100 mg/kg/day)”, and “high dose group (200 mg/kg/day)”. These mice were then injected test drug intraperitoneally once daily until the tumor size reached 100 mm 3 . The tumor sizes and body weight were measured twice a week. The tumor sizes were measured and calculated by formula: (L ⁇ W 2 )/2. L represents the tumor longest length. W represents the tumor shortest diameter. The experiment results were shown in Table 19
  • low dose and high dose of Azelnidipine had effectively slow down the tumor volume growth, and can also reduce the tumor volume.
  • high dose of Azelnidipine had better effect to inhibit tumor growth.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of Azelnidipine or a pharmaceutical acceptable salt thereof. The cancer is selected from the group consisting of a pleural-related cancer, an abdominal-related cancer, an endocrine-related cancer, a gastrointestinal tract-related cancer, osteosarcoma, and skin cancer.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This is a National Phase Application filed under 35 U.S.C. 371 as a national stage of PCT/CN2015/092714 filed Oct. 23, 2015, an application claiming the benefit under 35 USC 119(e) to the following U.S. Provisional Applications No. 62/068,298 filed Oct. 24, 2014, the content of each of which is hereby incorporated by reference in its entirety.
    • FIELD OF THE INVENTION
  • The present invention related to a new indication of Azelnidipine pharmaceutical composition, especially related to inhibition effect of Azelnidipine pharmaceutical composition on a variety of cancer cells.
    • BACKGROUND OF THE INVENTION
  • Azelnidipine is a drug for treating hypertension and can be used alone or in combination with other antihypertensive drugs. Azelnidipine is approved by FDA and accumulated a huge data of drug use and drug mechanism research.
  • Due to the differences of the clinical use, there is no research present that the Azelnidipine has any potential to inhibit cancer cell.
  • On the other side, cancer is the most popular disease cause of death in the world. The cancer patients are gradually increase yearly, therefore the treatment method of the cancer has become an important issue. The medical treatments of cancer can be classified as surgical treatment, radiation therapy, chemotherapy and target therapy. Generally, the cancer drug, whether chemotherapy drug or target therapy drug, is to inhibit cancer cells duplication and split to prevent the tumor growth and metastasis. Averagely, only about five of 10,000 new drugs can successfully enter the phase I of clinical trials. Furthermore, if the cancer patients happen the drug resistance, that would reduce the effectiveness of the drugs and result in the medical treatment failure. Therefore, the new drug development is very difficult.
  • Therefore, it is a very urgent and important issue that how to develop anti-cancer drugs quickly and reduce the probability of clinical failure for treating various cancers.
    • SUMMARY OF THE INVENTION
  • In order to solve the above problems, the present invention provide the development of new cancer clinical indications of Azelnidipine.
  • Accordingly, the present invention provides a new indication of Azelnidipine. The experimental results showed that the Azelnidipine had no toxicity or had little toxicity to normal cells in the present invention. However, the selective effect of Azelnidipine between normal cells and cancer cells need to be identified.
  • The present invention provides a pharmaceutical composition of Azelnidipine for treating cancer. The pharmaceutical composition is composed of effective dose of Azelnidipine and a pharmaceutical acceptable salt.
  • In one embodiment of the present invention, the cancer is selected from pleural-related cancer, abdominal-related cancer, endocrine-related cancer, gastrointestinal tract-related cancer.
  • In one embodiment of the present invention, the cancer is selected from osteosarcoma, skin cancer and blood cancer.
  • In one embodiment of the present invention, the pleural-related cancer is lung cancer.
  • In one embodiment of the present invention, the abdominal-related cancer is selected from bladder cancer, cervical cancer, and kidney cancer.
  • In one embodiment of the present invention, the endocrine-related cancer is selected from prostate cancer, breast cancer, and ovarian cancer.
  • In one embodiment of the present invention, the gastrointestinal tract-related cancer is selected from gastric cancer, hepatic cancer, colorectal cancer, pancreatic cancer, and tongue cancer.
  • In one embodiment of the present invention, the effective dose of Azelnidipine is from 2.0 mg/kg/day to 500 mg/kg/day.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows the results of the inhibitory effect of the different cancer cells by Azelnidipine.
  • FIG. 2 shows the results of the inhibitory effect of tumor volume by Azelnidipine.
  • FIG. 3 shows the inhibitory effect of tumor growth via administered high-dose and low-dose of Azelnidipine.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • Cell Culture
  • Subculture the different types of cancer cell lines. The cancer cells includes lung cancer, gastric cancer, hepatic cancer, colon cancer, skin cancer, cervical cancer, prostate cancer, bladder cancer, breast cancer, leukemia, pancreatic cancer, ovarian cancer, tongue cancer, osteosarcoma, and renal cancer. The normal cells used in the control group included kidney cell (HEK293) and human bronchial epithelial cell line BEAS-2B (as shown in Table 1).
  • Cancer cell lines were cultured in different culture medium according to different characteristics (as shown in Table 1). The cell numbers were counted and reseed as 2×106 in cell culture plate/flask. Then, the culture medium were added to a volume of 10 ml, and the cells were cultured for 2-3 days. Then, the cells were suspended for loading into 96-well plates. The number of cells was 3000 and the volume of the culture medium was 100 μl each well.
  • TABLE 1
    Cancer cell lines and the culture medium
    Culture
    No Cancer type Cancer cell type medium
    1 lung H1650 (lung adenocarcinoma) RPMI-1640
    cancer A549 (lung adenocarcinoma) DMEM
    2 gastric AGS (Gastric Adenocarcinoma) RPMI-1640
    cancer MKN-45 (Gastric Adenocarcinoma) RPMI-1640
    3 hepatic HepG2 (hepatocellular carcinoma) DMEM
    cancer Hep3B (hepatocellular carcinoma) DMEM
    4 colon HCT116(p53+) (colorectal carcinoma) DMEM
    cancer LoVo(Colorectal Adenocarcinoma) DMEM
    5 skin A375 (amelanotic melanoma) DMEM
    cancer BCC (basal cell carcinoma) DMEM
    6 cervical HeLa (Cervix Adenocarcinoma) DMEM
    cancer C-33A (Cervical carcinoma) MEM
    BCRC60554
    7 prostate PC3 (p53−)(Prostate adenocarcinoma) DMEM
    cancer LNCaP clone FGC (LNCap.FGC) RPMI-1640
    8 bladder 8301 (urinary bladder carcinoma) RPMI-1640
    cancer T24 RPMI-1640
    9 breast MCF7 (Mammary Gland, DMEM
    cancer Adenocarcinoma) DMEM
    MDA-MB-231 (Mammary Gland,
    Adenocarcinoma)
    10 pancreatic BxPC-3 RPMI-1640
    cancer AsPC-1 RPMI-1640
    11 ovarian NIH: OVCAR-3 RPMI-1640
    cancer TOV-21G RPMI-1640
    12 tongue SAS (Tongue squamous cell carcinoma) DMEM
    cancer
    13 osteo- U-2OS DMEM
    sarcoma
    14 renal 786-O (Renal adenocarcinoma) RPMI-1640
    cancer BCRC 60243
    15 normal cell HEK293 (Kidney) DMEM
    kidney BEAS-2B (Lung Epithelial) RPMI-1640
    pulmonary
    epithelial
    cell line
  • Cell Viability Analysis
  • Removing the original culture medium from 96-well plate. Then add 100 μl of commercially drug at a concentration of 10 μM per well. After 72 hours, add the diluted WST-1 reagent to the well with 100 μl/well, and the diluted WST-1 reagent was acquired from the dilution of 9:1 medium and WST-1 stock reagent. Finally, the total volume of each well was 200 μl/well. Culture the 96-well plate at 37° C. for 30 to 90 minutes. Detecting and calculate the survival rate of each cancer cells with an ELISA reader at OD450 nm. The lower viability of cancer cells represents better inhibition effect via the Azelnidipine drug. Otherwise, the higher viability of cancer cells represents worse inhibition effect via the Azelnidipine drug.
  • The Effect of Azelnidipine on Different Cancer Cell Lines
  • The Inhibition Effect of Azelnidipine on Pleural-Related Cancer Cells
  • This inhibition test of Azelnidipine on pleural-related cancer cells were using two lung cancer cell lines A549 and H1650. The inhibitory tests of Azelnidipine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 2.
  • TABLE 2
    The inhibition effect of Azelnidipine on pleural-related cancer cells
    0524-10 0526-10 0529-10 0531-10
    min min min min Average
    A549 81.4 118.6 69.7 80.2 87.5
    1-10 2-20 3-20 4-20
    min min min min Average
    H1650 28.8 26.5 40.5 62.7 39.7
  • The Inhibition Effect of Azelnidipine on Abdominal-Related Cancer Cell Lines
  • This inhibition test of Azelnidipine on abdominal-related cancer cells were using bladder cancer cell line TSGH and T24 (Table 3), cervical cancer cell lines HeLa and C-33A (Table 4), renal cancer cell line 786-O (Table 5). The inhibitory tests of Azelnidipine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 3, Table 4, and Table 5.
  • TABLE 3
    The inhibition effect of Azelnidipine on bladder cancer cell lines
    0510-10 0512-10 0515-10 0517-10
    min min min min average
    TSGH 151.0 117.3 72.0 120.1 115.1
    1-30 2-20 3-20 4-20
    min min min min average viability
    T24 109.7 75.3 30.4 102.5 79.5
  • TABLE 4
    The inhibition effect of Azelnidipine on cervical cancer cell lines
    0524-10 0526-10 0529-10 0531-10
    min min min min Average
    HeLa 70.4 93.7 81.4 102.7 87.0
    C-33A 141.8 110.6 123.4 117.4 123.3
  • TABLE 5
    The inhibition effect of Azelnidipine on renal cancer cell line
    0524-10 0526-10 0529-10 0531-10
    min min min min average
    786-O 88.6 79.7 66.5 112.5 86.8
  • The Inhibition Effect of Azelnidipine on Endocrine-Related Cancer Cell Lines
  • This inhibition test of Azelnidipine on endocrine-related cancer cells were using prostate cancer cell line PC-3 (Table 6), breast cancer cell lines MCF7 and MDA-MB-231 (Table 7), and ovarian cancer cell lines NIH-OVCAR-3 and TOV-21G (Table 8). The inhibitory tests of Azelnidipine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 6, Table 7, and Table 8.
  • TABLE 6
    The inhibition effect of Azelnidipine on prostate cancer cell line
    PC-3-0524- PC-3-0526- PC-3-0529- PC-3-0531- Aver-
    10 min 10 min 10 min 10 min age
    PC-3 122.1 149.4 110.2 102.0 120.9
  • TABLE 7
    The inhibition effect of Azelnidipine on breast cancer cell lines
    0612-10 0614-10 0616-10 0619-10
    min min min min average
    MCF7 48.6 46.6 68.2 79.9 60.8
    0612-10 0614-10 0616-10
    min min min average
    MDA-MB-231 70.3 89.7 100.8 86.9
  • TABLE 8
    The inhibition effect of Azelnidipine on ovarian cancer cell lines
    7-3-30 7-4-30 7-7-30 7-4-30
    min min min min average
    NIH-OVCAR-3 106.3 99.1 100.9 103.5 102.4
    7-3-30 7-4-30 7-7-30 4-30
    min min min min average
    TOV-21G 15.6 13.3 19.6 60.1 27.2
  • The Inhibition Effect of Azelnidipine on Gastrointestinal Tract-Related Cancer Cell Lines
  • This inhibition test of Azelnidipine on gastrointestinal tract-related cancer cells were using gastric cancer cell lines AGS and MKN-45 (Table 9), hepatic cancer cell lines HepG2 and Hep3B (Table 10), colorectal cancer cell lines HCT116-wt and LoVo (Table 11), pancreatic cancer cell lines AsPC-1 and BxPC-3 (Table 12), tongue cancer cell line SAS (Table 13). The inhibitory tests of Azelnidipine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 9, Table 10, Table 11, Table 12 and Table 13.
  • TABLE 9
    The inhibition effect of Azelnidipine on gastric cancer cell lines.
    0510-10 0512-10 0515-10 0517-10
    min min min min average
    AGS 120.2 124.3 42.1 74.3 90.2
    0510-10 0512-10 0515-10 0517-10
    min min min min Average
    MKN-45 173.5 183.7 68.5 130.3 139.0
  • TABLE 10
    The inhibition effect of Azelnidipine on hepatic cancer cell lines
    0524-20 0526-20 0529-20 0531-20
    min min min min Average
    HepG2 110.3 87.2 112.1 93.7 100.8
    0612-20 0614-20 0616-20 0619-20
    min min min min Average
    Hep3B 114.2 91.5 97.9 90.7 98.6
  • TABLE 9
    The inhibition effect of Azelnidipine on colorectal cancer cell lines
    0602-30 0605-10 0607-10 0609-10
    min min min min Average
    HCT116-wt 70.7 146.2 158.9 69.3 111.3
    0616-10 0619-10 0621-10 0623-10
    min min min min Average
    LoVo 49.6 67.2 62.3 60.3 59.9
  • TABLE 12
    The inhibition effect of Azelnidipine on pancreatic cancer cell lines
    1-7-3-30 1-7-4-30 1-7-7-30 1-4-30
    min min min min Average
    AsPC-1 103.9 46.1 13.7 58.6 55.6
    3-7-3-30 3-7-4-30 3-7-7-30 3-4-30
    min min min min Average
    BxPC-3 79.9 51.0 50.0 77.5 64.6
  • TABLE 13
    The inhibition effect of Azelnidipine on tongue cancer cell line
    6-26-10 6-28-10 6-30-10 7-3-10
    min min min min Average
    SAS 69.9 66.0 66.7 104.7 76.8
  • The Inhibition Effect of Azelnidipine on Other Cancer Cell Lines
  • This inhibition test of Azelnidipine on other cancer cells were using osteosarcoma cell line U2OS (Table 14), skin cancer cell lines A375 and BCC (Table 15). The inhibitory tests of Azelnidipine were performed 3 to 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 14 and Table 15.
  • TABLE 14
    The inhibition effect of Azelnidipine
    on osteosarcoma cancer cell line
    6-26-10 6-28-10 6-30-10 7-3-10
    min min min min Average
    U2OS 53.3 78.3 84.8 61.2 69.4
  • TABLE 15
    The inhibition effect of Azelnidipine on skin cancer cell lines
    0602-30 0605-10 0607-10 0609-10
    min min min min Average
    A375 123.6 100.2 76.0 104.9 101.2
    0602-30 0605-10 0607-10
    min min min Average
    BCC 77.7 127.2 95.7 100.2
  • The Experiment Design on Control Group
  • The Inhibition Effect of Azelnidipine on Normal Cells
  • This inhibition test of Azelnidipine on normal cells were using normal kidney cell line HEK293 (Table 16) and normal pulmonary epithelial cell lines BEAS-2B (Table 17). The inhibitory tests of Azelnidipine were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 16 and Table 17.
  • TABLE 16
    The inhibition effect of Azelnidipine on normal kidney cell line
    Average
    HEK293 94.2
  • TABLE 17
    The inhibition effect of Azelnidipine on
    normal pulmonary epithelial cell line
    0510-10 0512-10 0515-10 0517-10
    min min min min average
    BEAS-2B 61.3 61.8 101.6 85.4 77.5
  • This inhibition test results of Azelnidipine on all kinds of cells were shown in Table 18. It is clear that Azelnidipine has a significant inhibitory effect on several cancers cell lines. As a result in the experiments of the present invention. Paroxetine has a significant inhibitory effect on various cancer cells (FIG. 1).
  • TABLE 18
    Summary of the Effect on different
    cancer cell lines by Azelnidipine
    Inhibitory effect
    cancer cells
    lung cancer 63.60
    bladder cancer 97.30
    cervical cancer 87.00
    Kidney cancer 86.80
    prostate cancer 60.45
    breast cancer 73.85
    ovarian cancer 64.80
    gastric cancer 114.60
    hepatic cancer 99.70
    colorectal cancer 85.60
    pancreatic cancer 60.10
    tongue cancer 76.80
    osteosarcoma 69.40
    skin cancer 100.70
    Normal cell
    Kidney cell 94.20
    pulmonary epithelial cell line 77.50
  • Animal Model Test of Ovarian Cancer with Dose 100 mg/kg/Day and 200 mg/kg/day
  • In this invention, the female mice were (BALB/cAnN.Cg-Foxn1nu/CrlNarl) purchased from National Laboratory Animal Center (Taiwan)). The weight of the mice were 21±1 g. These mice were subcutaneously injected with gastric cancer cells (AGS) and then put these mice into different cages at random. The drug test experiment was divided into three groups, include “normal control group”, “low dose group (100 mg/kg/day)”, and “high dose group (200 mg/kg/day)”. These mice were then injected test drug intraperitoneally once daily until the tumor size reached 100 mm3. The tumor sizes and body weight were measured twice a week. The tumor sizes were measured and calculated by formula: (L×W2)/2. L represents the tumor longest length. W represents the tumor shortest diameter. The experiment results were shown in Table 19
  • TABLE 19
    The inhibitory effect of tumor volume via administered Azelnidipine
    control group low dose (100 mg/kg/day) high dose (200 mg/kg/day)
    tumor tumor tumor
    longest vol- volume longest volume longest volume
    weight length width ume growth weight length width volume growth weight length width volume growth
    (g) mm mm mm3 mm3 (g) mm mm mm3 mm3 (g) mm mm mm3 mm3
    First measurement
    A 18.5 7 7 171.5 171.5 21 8 8 256 256 20 4 3 18 18
    B 22 8 6 144 144 21 6 7 147 147 19.5 6 3 27 27
    C 20.5 9 8 288 288 21 7 6 126 126 20 4 4 32 32
    av- 20.4 7.6 7 189.3 189.3 176.3333 176.3333 25.66667 25.66667
    er-
    age
    Second measurement
    A 22 7 6 126 −45.5 20 7 6 126 −130 19 7 5 87.5 69.5
    B 20 8 7 196 52 20 6 6 108 −39 20 6 5 75 48
    C 20 9 7 220.5 −67.5 19 5 5 62.5 −63.5 19 7 5 87.5 55.5
    av- 20.6 8.4 6.8 198.5 9.2 98.83333 −77.5 83.33333 57.66667
    er-
    age
    Third measurement
    A 23 9 6 162 36 19.5 7 6 126 0 20.5 7 5 87.5 0
    B 20 10 8 320 124 19 6 6 108 0 19 5 5 62.5 −12.5
    C 21 11 7 269.5 49 18.5 5 5 62.5 0 20 0 0 0 −87.5
    av- 21.2 10 6.8 235.3 36.8 98.83333 0 50 −33.3333
    er-
    age
    Fourth measurement
    A 23 11 7 269.5 107.5 20 4 3 18 −108 20 0 0 0 −87.5
    B 22 10 6 180 −140 21 5 4 40 −68 20 0 0 0 −62.5
    C 23 11 8 352 82.5 20 0 0 0 −88 21 0 0 0 0
    av- 22.4 233.5 −1.8 19.33333 −88 0 −50
    er-
    age
    Fifth measurement
    A 22 12 8 384 114.5 20 4 3 18 0 20 0 0 0 0
    B 22 11 8 352 172 20 6 4 48 8 20 0 0 0 0
    C 23 12 9 486 134 21 0 0 0 0 21 0 0 0 0
    av- 22.4 295.7 62.2 22 2.666667 0 0
    er-
    age
  • According to the results in FIG. 2, low dose and high dose of Azelnidipine had significant inhibition effect on tumor cells. In the meantime, the weight of mice did not show a significant decrease during the experiment. These results indicated that both high and low doses of Azelnidipine could keep the tested mice in healthy status during the treatment without death.
  • According to the results in FIG. 3, low dose and high dose of Azelnidipine had effectively slow down the tumor volume growth, and can also reduce the tumor volume. Especially, high dose of Azelnidipine had better effect to inhibit tumor growth.
  • Although the present invention has been described in terms of specific exemplary embodiments and examples, it will be appreciated that the embodiments disclosed herein are for illustrative purposes only and various modifications and alterations might be made by those skilled in the art without departing from the spirit and scope of the invention as set forth in the following claims.

Claims (8)

1. A method for treating a cancer comprising: administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of Azelnidipine or a pharmaceutical acceptable salt thereof.
2. The method of claim 1, wherein the cancer is selected from the group consisting of a pleural-related cancer, an abdominal-related cancer, an endocrine-related cancer, and a gastrointestinal tract-related cancer.
3. The method of claim 1, wherein the cancer is selected from is selected from the group consisting of osteosarcoma and skin cancer.
4. The method of claim 2, wherein the cancer pleural-related cancer is lung cancer.
5. The method of claim 2, wherein the abdominal-related cancer is selected from the group consisting of bladder cancer, cervical cancer, and kidney cancer.
6. The method of claim 2, wherein the endocrine-related cancer is selected from the group consisting of prostate cancer, breast cancer, and ovarian cancer.
7. The method of claim 2, wherein the gastrointestinal tract-related cancer is selected from the group consisting of gastric cancer, hepatic cancer, colorectal cancer, pancreatic cancer, and tongue cancer.
8. The method of claim 1, wherein the effective amount of Azelnidipine is from 2.0 mg/kg/day to 500 mg/kg/day.
US15/521,500 2014-10-24 2015-10-23 New indication of azelnidipine pharmaceutical composition for treating cancer Abandoned US20170312260A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/521,500 US20170312260A1 (en) 2014-10-24 2015-10-23 New indication of azelnidipine pharmaceutical composition for treating cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068298P 2014-10-24 2014-10-24
PCT/CN2015/092714 WO2016062275A1 (en) 2014-10-24 2015-10-23 Use of azelnidipine in preparing medicinal composition for treating cancers
US15/521,500 US20170312260A1 (en) 2014-10-24 2015-10-23 New indication of azelnidipine pharmaceutical composition for treating cancer

Publications (1)

Publication Number Publication Date
US20170312260A1 true US20170312260A1 (en) 2017-11-02

Family

ID=55760314

Family Applications (7)

Application Number Title Priority Date Filing Date
US15/521,540 Active US10098852B2 (en) 2014-10-24 2015-10-23 Indication of monobenzone pharmaceutical composition for treating cancer
US15/521,504 Abandoned US20170304228A1 (en) 2014-10-24 2015-10-23 New indication of cinacalcet hcl pharmaceutical composition for treating cancer
US15/521,517 Active US10105357B2 (en) 2014-10-24 2015-10-23 Indication of antibiotic drugs for preparation of cancer inhibition pharmaceutical composition
US15/521,536 Abandoned US20170304388A1 (en) 2014-10-24 2015-10-23 New indication of cardiovascular drugs for preparation of cancer inhibition pharmaceutical composition
US15/521,500 Abandoned US20170312260A1 (en) 2014-10-24 2015-10-23 New indication of azelnidipine pharmaceutical composition for treating cancer
US15/521,524 Abandoned US20170304286A1 (en) 2014-10-24 2015-10-23 New indication of paroxetine pharmaceutical composition for treating cancer
US15/492,859 Active US10045962B2 (en) 2014-10-24 2017-04-20 Uses of duloxetine HCL medicament in preparing pharmaceutical treatment of cancer

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US15/521,540 Active US10098852B2 (en) 2014-10-24 2015-10-23 Indication of monobenzone pharmaceutical composition for treating cancer
US15/521,504 Abandoned US20170304228A1 (en) 2014-10-24 2015-10-23 New indication of cinacalcet hcl pharmaceutical composition for treating cancer
US15/521,517 Active US10105357B2 (en) 2014-10-24 2015-10-23 Indication of antibiotic drugs for preparation of cancer inhibition pharmaceutical composition
US15/521,536 Abandoned US20170304388A1 (en) 2014-10-24 2015-10-23 New indication of cardiovascular drugs for preparation of cancer inhibition pharmaceutical composition

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/521,524 Abandoned US20170304286A1 (en) 2014-10-24 2015-10-23 New indication of paroxetine pharmaceutical composition for treating cancer
US15/492,859 Active US10045962B2 (en) 2014-10-24 2017-04-20 Uses of duloxetine HCL medicament in preparing pharmaceutical treatment of cancer

Country Status (9)

Country Link
US (7) US10098852B2 (en)
EP (3) EP3210604B1 (en)
JP (1) JP6539345B2 (en)
KR (1) KR102490334B1 (en)
CN (3) CN106999470A (en)
AU (2) AU2015335391B2 (en)
ES (2) ES2973279T3 (en)
TW (21) TWI621434B (en)
WO (21) WO2016062278A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049976T2 (en) 2005-12-28 2020-11-30 Vertex Pharma Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2016062278A1 (en) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 Applications of endocrine disease medicaments in preparing cancer-inhibiting pharmaceutical composition
EP3236967B1 (en) 2014-12-22 2019-10-16 SUDA Pharmaceuticals Ltd Prevention and treatment of metastatic disease in thrombocytotic cancer patients
WO2017116049A1 (en) * 2015-12-31 2017-07-06 경북대학교 산학협력단 Pharmaceutical composition for treating cancer and suppressing metastasis, containing sulfonamide-based compound as active ingredient
EP3241562A1 (en) * 2016-05-02 2017-11-08 Fundació Institut Mar d'Investigacio Medica Zonisamide for use in the treatment of breast cancer
CN106074474A (en) * 2016-06-15 2016-11-09 中南大学湘雅医院 Benserazide and pharmaceutically application in terms of preparing antineoplastic for the acceptable salt
WO2018072135A1 (en) * 2016-10-19 2018-04-26 微菌方舟生物科技股份有限公司 Use of dihydropyridine calcium antagonist in treating cancer
CN108066345A (en) * 2016-11-14 2018-05-25 武汉华杰世纪生物医药有限公司 A kind of compound with antitumor action
CN115813888A (en) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 Transdermal therapeutic system comprising asenapine
EP3558276A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
WO2018227129A1 (en) * 2017-06-09 2018-12-13 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
JP2020525545A (en) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー Transdermal therapeutic system containing asenapine and silicone-acrylic hybrid polymer
EP3648764A4 (en) * 2017-07-03 2021-03-31 Menri Group Ltd. Treatment of cancer with dihydropyridines
JP2019064976A (en) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 Anticancer agents
KR101933805B1 (en) 2017-10-17 2018-12-28 성균관대학교산학협력단 Pharmaceutical Composition for Preventing or Treating brain tumor comprising Oxeladin citrate as Active Ingredients
CN108186652A (en) * 2017-12-28 2018-06-22 深圳大学 Gap connects iuntercellular communication inhibitor 18-BETA-Glycyrrhetinic acid and is preparing the application in preventing and treating hepatocellular carcinoma drug
US11911351B2 (en) 2018-01-30 2024-02-27 Apnimed, Inc. (Delaware) Methods for treating sleep apnea with combinations of atomoxetine and (R)-oxybutynin
US11931366B2 (en) * 2018-04-19 2024-03-19 Washington University Compositions and methods of use thereof for treatment of proteinopathies
MX2020014286A (en) 2018-06-20 2021-03-25 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system containing asenapine.
FR3090084B1 (en) 2018-12-18 2023-10-13 Securengy Projectile for firearms or compressed air for liquid or powder delivery.
WO2020132253A1 (en) * 2018-12-19 2020-06-25 University Of Vermont And State Agricultural College Cancer therapeutic compositions and methods
US20220193020A1 (en) * 2019-04-04 2022-06-23 Daegu-Gyeongbuk Medical Innovation Foundation Pharmaceutical Composition Comprising Trimebutine or Pharmaceutically Acceptable Salt Thereof as an Active Ingredient For Prevention or Treatment of Cancer
US20220202771A1 (en) * 2019-04-05 2022-06-30 University Of North Texas Health Science Center At Fort Worth Antidepressants for the Treatment or Prevention of Memory Loss and/or Cognitive Decline or Dysfunction in Aging
CA3136353A1 (en) * 2019-04-11 2020-10-15 Ian Basil Shine Cell membrane permeability restoring therapy
CN110179803A (en) * 2019-05-31 2019-08-30 天津科技大学 A kind of application of thioxanthene bromine class compound
CN110742890A (en) * 2019-10-24 2020-02-04 暨南大学 Application of lomerizine in preparation of anti-colon cancer drug
CN110876800B (en) * 2019-11-18 2023-06-27 中南大学 Application of micafungin in preparation of antitumor drugs and antitumor drugs
CN110840887A (en) * 2019-11-18 2020-02-28 杭州彗搏科技有限公司 Application of triclabendazole in preparation of medicine for treating breast cancer
CN111067899B (en) * 2020-01-08 2021-03-05 温州医科大学 Application of antimalarial primaquine phosphate in preparation of drugs for treating leukemia
US11304969B2 (en) * 2020-01-24 2022-04-19 The Florida International Univeristy Board Of Trustees Treatments of prostate cancer
CN111973593A (en) * 2020-05-09 2020-11-24 深圳市罗湖区人民医院 Application of nitazoxanide and pharmaceutically acceptable salt thereof in preparation of medicines for treating bladder cancer
CN111557941A (en) * 2020-06-15 2020-08-21 浙江大学 Application of small-molecule inhibitor minoxidil of PLOD2 in tumor treatment
CN111848717A (en) * 2020-08-07 2020-10-30 四川大学 Compound for targeted regulation of mitochondrial energy metabolism and application and medicament thereof
WO2022033459A1 (en) * 2020-08-10 2022-02-17 萧乃文 Use of double non-oncology drug in preparation of pharmaceutical composition for treating cancers
CN112274525B (en) * 2020-12-04 2022-04-08 遵义医科大学 Chemotherapy pharmaceutical composition and application thereof
CN112336725A (en) * 2020-12-11 2021-02-09 吴照球 Novel medical application of trimethoprim
CN112569342A (en) * 2020-12-21 2021-03-30 中南大学 Application of caspofungin and/or pharmaceutical salt thereof in preparation of antitumor drugs and antitumor drugs
CN112569215A (en) * 2020-12-30 2021-03-30 东莞市人民医院 Application of domiphen bromide in preparation of medicine for preventing and treating colorectal cancer
EP4108244A1 (en) * 2021-06-25 2022-12-28 Universität Regensburg Ss-lactam antibiotic with significant activity against cancer e.g. colon malignancies
CN113663071B (en) * 2021-06-28 2022-12-30 四川大学 Use of FBXL2 activator for preparing medicine for treating EGFR driven lung cancer
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
CN117642164A (en) * 2021-09-09 2024-03-01 中国福利会国际和平妇幼保健院 Application of penfluridol in preparing medicine for treating endometrial cancer
CN115887455B (en) * 2022-08-04 2024-04-05 北京大学人民医院 Application of azelnidipine serving as calcium channel blocker in preparation of medicines for treating endometrial cancer
CN115778957B (en) * 2022-11-04 2024-06-21 天津中医药大学 Application of cepharanthine and composition containing cepharanthine in preventing or treating alcoholic liver disease
CN116570579A (en) * 2023-06-13 2023-08-11 深圳市泛谷药业股份有限公司 Pharmaceutical composition containing agomelatine and fluvoxamine and application thereof
CN118059099B (en) * 2024-04-19 2024-06-14 四川大学华西医院 Application of paroxetine combined with ASCT2 inhibitor in preparation of medicines for treating liver cancer and medicine composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
US20170020835A1 (en) * 2014-04-08 2017-01-26 The Methodist Hospital Inos-inhibitory compositions and their use as breast cancer therapeutics

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3844491B2 (en) * 1993-10-01 2006-11-15 シンテックス（ユー・エス・エイ）インコーポレイテッド Mycophenolate mofetil high-dose oral suspension
CN1167418C (en) * 1994-12-28 2004-09-22 詹森药业有限公司 Use of nebivolol as anti-atherogenic
SI1113797T1 (en) * 1998-09-15 2010-02-26 Lilly Co Eli Use of duloxetine for the treatment of fibromyalgia
US6927223B1 (en) * 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
ATE544745T1 (en) * 2000-07-07 2012-02-15 Tufts College 9-SUBSTITUTED MINOCYCLINE COMPOUNDS
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP2007505914A (en) * 2003-09-18 2007-03-15 コンビナトアールエックス インコーポレーティッド Drug combination methods for the treatment of neoplasms
ZA200603718B (en) * 2003-11-06 2007-09-26 Celgene Corp Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
EP1753425A4 (en) * 2004-05-12 2009-08-05 Biorunx Co Ltd A therapeutic agent containing nicotinic acid or its derivatives as an effective ingredient for prevention and treatment of cancer
AU2005244988C1 (en) * 2004-05-21 2012-06-28 President And Fellows Of Harvard College Synthesis of tetracyclines and analogues thereof
CN1279980C (en) * 2004-10-14 2006-10-18 孔庆忠 Anti solid tumor medicine composition
JP2006298781A (en) * 2005-04-15 2006-11-02 Geno Membrane:Kk Estrone-3-sulfate transporter activity inhibitor
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
CN101223149A (en) * 2005-07-05 2008-07-16 特瓦制药工业有限公司 Process for preparing valsartan
AU2005334836B2 (en) * 2005-07-28 2012-04-12 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Sensitization of immune system against haptenized melanoma antigens
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
MX2008012061A (en) * 2006-03-23 2008-12-17 Amgen Inc Methods and compositions for making and using polymorphs of cinacalcet.
CN101099724A (en) * 2006-07-07 2008-01-09 上海复旦复华药业有限公司 Micronization femara and its composition
CN101103976A (en) * 2006-07-14 2008-01-16 海南盛科生命科学研究院 Oral medicinal composition containing anastrozole and preparation technology thereof
US20100273868A1 (en) * 2007-01-05 2010-10-28 Cornerstone Therapeutics Inc. R-Zileuton for Use in Conditions Associated with Increased 5-Lipoxygenase and/or Leukotriene Activity (EG Asthma)
CN101730526A (en) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 Nanoparticle comprising rapamycin and albumin as anticancer agent
US20090137837A1 (en) * 2007-06-21 2009-05-28 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
WO2009025854A1 (en) * 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CN100563645C (en) * 2007-12-06 2009-12-02 济南帅华医药科技有限公司 A kind of Beisalutin sustained-release implantation agent for the treatment of entity tumor
US20090270397A1 (en) * 2008-04-08 2009-10-29 Orlow Seth J Methods and compositions for the treatment of cancers, such as melanomas and gliomas
CN101569624A (en) * 2008-04-29 2009-11-04 石药集团中奇制药技术（石家庄）有限公司 Application of amlodipine to preparation of medicaments for curing phoproliferative diseases
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
WO2009147169A1 (en) * 2008-06-03 2009-12-10 Universite Paris Diderot-Paris 7 Pharmaceuticl compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia
CN101612400A (en) * 2009-07-22 2009-12-30 陈志龙 1 application of receptor antagonist in antitumor of angiotensin
CN101690816A (en) * 2009-08-16 2010-04-07 王丽燕 Medicinal composition of calcium-containing antagonist, A II receptor antagonist and statins
CN101991553B (en) * 2009-08-21 2015-02-25 北京以岭生物工程技术有限公司 Exemestane tablet and preparation method thereof
CN101863806B (en) * 2010-03-18 2013-02-13 湖北省医药工业研究院有限公司 Preparation method of medicine (R)-Bicalutamide for resisting prostatic cancer
US9012511B2 (en) * 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
WO2012015023A1 (en) * 2010-07-29 2012-02-02 国立大学法人京都大学 Method for screening anticancer agents
US20130261142A1 (en) * 2010-12-15 2013-10-03 Hung-Cheng Lai Compounds used for treating cancer and the use thereof
CN102631354B (en) * 2011-02-11 2015-01-21 广东泰禾医药科技有限公司 Pharmaceutical composition containing vitamin D and metformin
CN102688493B (en) * 2011-03-25 2014-09-10 鼎泓国际投资（香港）有限公司 Pharmaceutical composition containing resveratrol, resveratrol derivative and Bc1-2 inhibitor, and application thereof
CN102813643B (en) * 2011-06-10 2014-09-24 北京蛋白质组研究中心 Application of bumetanide in inhibition of hepatoma cell transfer
US9757424B2 (en) * 2011-09-27 2017-09-12 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas
US20140315809A1 (en) * 2011-11-10 2014-10-23 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
CN102600077B (en) * 2012-03-29 2013-06-05 江苏豪森药业股份有限公司 Gemcitabine or gemcitabine salt nano-emulsion injecta and preparation method thereof
ES2384069B1 (en) * 2012-03-29 2013-07-04 Hospital Sant Joan De Déu Cinacalcet and neuroblastic tumors
CN103536607A (en) * 2012-07-10 2014-01-29 邵金辉 Anti-tumor effects of oxytetracycline, propafenone and dipyrone
WO2014036654A1 (en) * 2012-09-06 2014-03-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
AU2013318338B2 (en) * 2012-09-21 2017-05-25 Intensity Therapeutics, Inc Method of treating cancer
AU2013326463B2 (en) * 2012-10-04 2018-01-18 Ab Science Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
CN102872066B (en) * 2012-10-19 2014-07-02 厦门大学 Ivermectin and application of derivative thereof
US9622982B2 (en) * 2013-01-14 2017-04-18 Health Clinics Limited Cancer drug and uses
CN103933569B (en) * 2013-01-22 2017-01-11 复旦大学 Anti-lung cancer pharmaceutical composition, its application, pill case and package
WO2014164704A2 (en) * 2013-03-11 2014-10-09 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
US20140271727A1 (en) * 2013-03-18 2014-09-18 National Yang-Ming University Method of using an antidepressant for increasing immunity of a subject and treating cancer
CN104161759B (en) * 2013-05-16 2019-10-08 中国科学院上海药物研究所 The anticancer usage of anagrelide and its derivative
CN103396419A (en) * 2013-08-13 2013-11-20 海宁市绿升医药科技有限公司 Tumour photodynamic therapy medicine dihydroporphin e6-15-ethyl ester and preparation method thereof
CN103536925B (en) * 2013-10-28 2015-07-01 中国医学科学院基础医学研究所 Application of cardiac glycoside compound in treatment of non-small cell lung cancer
CN103622975B (en) * 2013-11-07 2016-06-15 广东药学院 Glipizide application in preparation tumor
WO2016062278A1 (en) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 Applications of endocrine disease medicaments in preparing cancer-inhibiting pharmaceutical composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
US20170020835A1 (en) * 2014-04-08 2017-01-26 The Methodist Hospital Inos-inhibitory compositions and their use as breast cancer therapeutics

Also Published As

Publication number Publication date
JP2017532351A (en) 2017-11-02
WO2016062289A1 (en) 2016-04-28
EP3210604A1 (en) 2017-08-30
US20170304388A1 (en) 2017-10-26
WO2016062287A1 (en) 2016-04-28
TW201615193A (en) 2016-05-01
TW201615222A (en) 2016-05-01
TW201615196A (en) 2016-05-01
TW201615224A (en) 2016-05-01
ES2973279T3 (en) 2024-06-19
WO2016062281A1 (en) 2016-04-28
AU2015335391B2 (en) 2018-06-21
CN107106523A (en) 2017-08-29
WO2016062290A1 (en) 2016-04-28
ES2954860T3 (en) 2023-11-27
WO2016062271A1 (en) 2016-04-28
TW201615218A (en) 2016-05-01
WO2016062278A1 (en) 2016-04-28
JP6539345B2 (en) 2019-07-03
TW201615191A (en) 2016-05-01
TW201615192A (en) 2016-05-01
CN107106550A (en) 2017-08-29
TWI621434B (en) 2018-04-21
TWI663984B (en) 2019-07-01
WO2016062285A1 (en) 2016-04-28
EP3210604A4 (en) 2018-06-27
TW201615195A (en) 2016-05-01
EP3222278A1 (en) 2017-09-27
WO2016062275A1 (en) 2016-04-28
WO2016062269A1 (en) 2016-04-28
US20170304387A1 (en) 2017-10-26
WO2016062279A1 (en) 2016-04-28
TW201615186A (en) 2016-05-01
WO2016062291A1 (en) 2016-04-28
EP3210604C0 (en) 2024-02-14
TW201615189A (en) 2016-05-01
AU2015335391A1 (en) 2017-06-01
WO2016062265A1 (en) 2016-04-28
WO2016062286A1 (en) 2016-04-28
WO2016062274A1 (en) 2016-04-28
US20170304218A1 (en) 2017-10-26
TW201615194A (en) 2016-05-01
TW201615197A (en) 2016-05-01
US10105357B2 (en) 2018-10-23
US20170304228A1 (en) 2017-10-26
EP3222278A4 (en) 2018-06-20
WO2016062266A1 (en) 2016-04-28
TW201615221A (en) 2016-05-01
TWI663969B (en) 2019-07-01
US10098852B2 (en) 2018-10-16
TWI652060B (en) 2019-03-01
CN106999470A (en) 2017-08-01
WO2016062270A1 (en) 2016-04-28
AU2015335375B2 (en) 2020-09-10
KR20170084034A (en) 2017-07-19
EP3235497A1 (en) 2017-10-25
TWI672150B (en) 2019-09-21
TW201615225A (en) 2016-05-01
TW201615184A (en) 2016-05-01
TW201615226A (en) 2016-05-01
WO2016062267A1 (en) 2016-04-28
US20170304286A1 (en) 2017-10-26
WO2016062277A1 (en) 2016-04-28
EP3222278B1 (en) 2023-06-14
WO2016062283A1 (en) 2016-04-28
WO2016062272A1 (en) 2016-04-28
TW201615219A (en) 2016-05-01
TW201615220A (en) 2016-05-01
TW201615188A (en) 2016-05-01
KR102490334B1 (en) 2023-01-18
AU2015335375A1 (en) 2017-05-18
US10045962B2 (en) 2018-08-14
EP3210604B1 (en) 2024-02-14
TW201615217A (en) 2016-05-01
WO2016062288A1 (en) 2016-04-28
EP3222278C0 (en) 2023-06-14
EP3235497A4 (en) 2018-06-13
TW201615223A (en) 2016-05-01
US20170216247A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
US10098852B2 (en) Indication of monobenzone pharmaceutical composition for treating cancer
Liu et al. In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog
Vitfell-Rasmussen et al. A phase I/II clinical trial of belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas
Palomares et al. All-trans-retinoic acid counteract the tumor-stimulating effect of hepatectomy and increases survival of rats bearing liver metastases
Deb et al. Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro
Bai et al. Inhibiting autophagy enhanced mitotic catastrophe-mediated anticancer immune responses by regulating the cGAS-STING pathway

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION